Clinical Scorecard: Cervical Cancer Screening Patterns Across Race and Ethnicity, Age, Language, and US Census Region
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Cervical Cancer Screening Patterns Across Race and Ethnicity, Age, Language, and US Census Region
Key Mechanisms
Routine screening can largely prevent cervical cancer; treatment is often successful when abnormalities are detected at a precancerous or early cancer stage.
Target Population
Analytic cohort: patients assigned female at birth, aged 21 to 64 years, with at least one clinical encounter in every year from 2019 through 2024 and no history of cervical cancer.
Care Setting
Care setting described in the source article.
Key Highlights
The study examined annual CCS patterns from 2019 through 2024 by race and ethnicity, age, language, and US Census region.
The analytic cohort included patients aged 21 to 64 years with encounters in every study year and no history of cervical cancer.
CCS receipt was identified using ICD-10, CPT, and HCPCS codes.
Age groups were 21 to 29, 30 to 49, and 50 to 64 years, reflecting screening guideline age distinctions described by the authors.
International records were included in overall analyses but excluded from US Census Region-stratified analyses.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The study assessed whether eligible patients received CCS at least once in each corresponding study year.
The article describes cytology-based screening for ages 21 to 29 and additional options, including high-risk HPV testing and cotesting, for ages 30 to 65.
Risks
The article summarizes prior research reporting screening disparities by race and ethnicity, age, rurality, and language proficiency.
The article reports reduced screening during the COVID-19 pandemic and cites prior research finding that reductions varied across population groups.
Patient & Prescribing Data
Patients assigned female at birth, aged 21 to 64 years, without a history of cervical cancer, and with at least one clinical encounter in every year from 2019 through 2024.
This study evaluated screening patterns, not treatment or prescribing. Screening receipt was identified from ICD-10, CPT, and HCPCS codes.
